Elasmogen Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Elasmogen Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11265
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Elasmogen Ltd (Elasmogen), formerly Pacific Shelf 1760 Ltd is a biopharmaceutical company that discovers and develops sight-saving therapies for the treatment of inflammatory diseases of the eye and inflammatory conditions of the gut. The company develops soloMER that are small (11 kDa) and stable proteins that have squeezed a fourth binding loop into their single domain format and are derived evolutionarily from a non-antibody lineage, placing them outside the complex or competitive antibody patent landscape. Its pipeline includes ELN/21 and ELN/22, which are auto-immune mediated anti-inflammatory programs; soloMER-drug-conjugates; and NDure, a soloMER humanized clinical candidate available for extending the plasma half-life of fused partner molecules, such as scFv, peptides, growth factors, single domains, and others. Elasmogen is headquartered in Aberdeen, the UK.

Elasmogen Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elasmogen Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Elasmogen Raises Funds through Equity Financing 10
Partnerships 11
Elasmogen, Feldan Bio Enter into Agreement with Amgen 11
Feldan Bio and Elasmogen Enter into Development Partnership 12
Elasmogen and Almac Discovery Enter into Co-Development Agreement 13
Equity Offering 14
Elasmogen Spin Off from University of Aberdeen 14
Elasmogen Ltd – Key Competitors 15
Elasmogen Ltd – Key Employees 16
Elasmogen Ltd – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Government and Public Interest 18
Aug 06, 2018: Almac discovery, Elasmogen and Innovate UK collaborate to develop VNAR based oncology platform 18
Mar 16, 2017: Elasmogen Receives £1.2 M In Grant And Equity Investment 19
Product News 20
Jan 20, 2017: Elasmogen – shark proteins for drug discovery 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Elasmogen Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elasmogen Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elasmogen Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Elasmogen Raises Funds through Equity Financing 10
Elasmogen, Feldan Bio Enter into Agreement with Amgen 11
Feldan Bio and Elasmogen Enter into Development Partnership 12
Elasmogen and Almac Discovery Enter into Co-Development Agreement 13
Elasmogen Spin Off from University of Aberdeen 14
Elasmogen Ltd, Key Competitors 15
Elasmogen Ltd, Key Employees 16

List of Figures
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Elasmogen Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • I-O Data Device, Inc. (6916):企業の財務・戦略的SWOT分析
    I-O Data Device, Inc. (6916) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Pharma Mar SA (PHM)-製薬・医療分野:企業M&A・提携分析
    Summary Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent, is indicated for the treatment of advanced …
  • Bryce Corporation:企業の戦略・SWOT・財務情報
    Bryce Corporation - Strategy, SWOT and Corporate Finance Report Summary Bryce Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • MEAG Munich Ergo AssetManagement GmbH:電力:M&Aディール及び事業提携情報
    Summary MEAG Munich Ergo AssetManagement GmbH (MEAG Munich), a subsidiary of Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft (Munich Re) is an asset management company that manages assets of Munich Re and ERGO Insurance Group and its affiliates. The company offers services such as asset …
  • Deutsche Lufthansa AG:企業のM&A・事業提携・投資動向
    Deutsche Lufthansa AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Deutsche Lufthansa AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Gilat Satellite Networks Ltd. (GILT):企業の財務・戦略的SWOT分析
    Gilat Satellite Networks Ltd. (GILT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Steinhoff International Holdings NV (SNH):企業の財務・戦略的SWOT分析
    Steinhoff International Holdings NV (SNH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Onorach Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Onorach Ltd (Onorach) is a contract research organization that provides clinical support services. The organization service portfolio includes tailored clinical trial support, clinical plan development, protocol design, regulatory, quality management, clinical operations management, patient …
  • Theraclion SA (ALTHE):企業の財務・戦略的SWOT分析
    Summary Theraclion SA (Theraclion) is a medical device company that designs, markets, and develops high-intensity focused therapeutic ultrasound devices and equipment; and offers technical support services. The company offers echotherapy solution that combines HIFU therapy with ultrasound as a syste …
  • Tidewater Holdings Inc:企業の戦略的SWOT分析
    Tidewater Holdings Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • DCM Shriram Ltd (DCMSHRIRAM):企業の財務・戦略的SWOT分析
    Summary DCM Shriram Ltd (DSL), formerly DCM Shriram Consolidated Ltd is a chemical company that manufactures and distributes chlor-vinyl and agricultural products. The company’s agricultural products include urea and SSP fertilizers, sugar, hybrid seeds, and farm solutions. Its chlor-vinyl products …
  • Energy Future Holdings Corp.-エネルギー分野:企業M&A・提携分析
    Summary Energy Future Holdings Corp. (EFH Corp) is an electric utility company. It manages a portfolio of competitive and regulated energy companies serving the Texas electricity market. The company’s competitive businesses consist of Luminant, which is involved in power generation and related minin …
  • QAD Inc (QADA):企業の財務・戦略的SWOT分析
    QAD Inc (QADA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Provogue (India) Limited (PROVOGE):企業の財務・戦略的SWOT分析
    Provogue (India) Limited (PROVOGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Klockner Pentaplast GmbH & Co. KG:企業の戦略・SWOT・財務情報
    Klockner Pentaplast GmbH & Co. KG - Strategy, SWOT and Corporate Finance Report Summary Klockner Pentaplast GmbH & Co. KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Quantum Fuel Systems LLC (QTWWQ):企業の戦略的SWOT分析
    Quantum Fuel Systems LLC (QTWWQ) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Endress+Hauser AG:企業の戦略的SWOT分析
    Endress+Hauser AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Qurient Co Ltd (115180)-製薬・医療分野:企業M&A・提携分析
    Summary Qurient Co Ltd (Qurient) is a biotechnology company that focuses on the development of new drugs for unmet medical needs. The company’s portfolio of pipeline products includes Q301, Q203, Q701, 5LO INH and CDK7 INH among others. The company is developing products for the treatment of atopic …
  • Quark Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Quark Pharmaceuticals Inc (Quark), a subsidiary of SBI Biotech Co Ltd, is a clinical-stage pharmaceutical company in the development of novel RNAi-based therapeutics. It offers under development products which include PF-655, a synthetic siRNA which is used for the treatment of diabetic macu …
  • Quantum Fuel Systems LLC (QTWWQ):電力:M&Aディール及び事業提携情報
    Summary Quantum Fuel Systems LLC (Quantum) is a provider of natural gas storage systems, integration and vehicle system technologies. The company produces advanced and lightweight compressed natural gas (CNG) storage tanks and fully integrated natural gas storage systems and supplies these tanks to …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆